pioglitazone has been researched along with Inflammatory Bowel Diseases in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD." | 3.77 | Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. ( Bassaganya-Riera, J; Climent, M; Evans, C; Guri, AJ; Hontecillas, R; Horne, WT; Sobral, BW; Zhang, Y, 2011) |
| " The present study aimed to investigate the effect of different doses of pioglitazone alone and in combination with sulfasalazine in TNBS (trinitrobenzenesulfonic acid)-induced inflammatory bowel disease (IBD) in rats." | 1.39 | Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. ( Byrav D S, P; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A; Vaiphei, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| da Rocha, GHO | 1 |
| Loiola, RA | 1 |
| de Paula-Silva, M | 1 |
| Shimizu, F | 1 |
| Kanda, T | 1 |
| Vieira, A | 1 |
| Gosselet, F | 1 |
| Farsky, SHP | 1 |
| Byrav D S, P | 1 |
| Medhi, B | 1 |
| Prakash, A | 1 |
| Chakrabarti, A | 1 |
| Vaiphei, K | 1 |
| Khanduja, KL | 1 |
| Hontecillas, R | 1 |
| Horne, WT | 1 |
| Climent, M | 1 |
| Guri, AJ | 1 |
| Evans, C | 1 |
| Zhang, Y | 1 |
| Sobral, BW | 1 |
| Bassaganya-Riera, J | 1 |
3 other studies available for pioglitazone and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood-Brain Barrier Model.
Topics: Blood-Brain Barrier; Claudin-5; Humans; Inflammation; Inflammatory Bowel Diseases; Intercellular Adh | 2022 |
Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Co | 2013 |
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Colon; Computational Biology; Dextran S | 2011 |